The independent source for health policy research, polling, and news.
Showing 61 - 80 of 114
Chances are, if you aren鈥檛 older, chronically ill, or obese, you don鈥檛 need a forthcoming covid vaccine to stay out of the hospital. But it probably wouldn鈥檛 hurt.
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer鈥檚, experts say.
At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients.
Black patients and other minorities tend to be diagnosed at later stages of the disease, which would exclude them from use of Leqembi. Few Black people were included in the main trial of the drug.
A quality-control crisis at an Indian pharmaceutical factory has left doctors and their patients with impossible choices as cheap, effective, generic cancer drugs go out of stock.
Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by then-President Donald Trump.
Drugmakers, pharmacies, and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?
Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.
The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn鈥檛 clear whether Sanders will succeed in even that, but he has put affordability front and center.
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it鈥檚 the arbitrators that jack up prices for those who can least afford them.
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of 鈥淢edicare for All鈥 maps out his strategy for negotiating with Republicans 鈥 and Big Pharma.
Pharmacy closures by two of the biggest home infusion companies point to grave shortages and dangers for patients who require IV nutrition to survive.
The Vaccines for Children program, which buys more than half the pediatric vaccines in the U.S., may not cover the RSV shot for babies because it鈥檚 not technically a vaccine.
A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.
While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.
While sales of its covid vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It鈥檚 sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals 鈥 which may pay nearly as little for the drug 鈥 charging so much more to administer it?
Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency鈥檚 reviews have gone much faster 鈥 perhaps too fast.
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn鈥檛 materialized.
Stay informed by signing up for the Morning Briefing and other emails:
漏 2026 KFF